Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients
Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients
复制标题
DOI：
10.1016/j.bbmt.2015.12.025
复制
发表时间：
2016-04-01
影响因子：
4.3
通讯作者：
Hanada, Ryoji
中科院分区：
文献类型：
--
作者：
Aoki, Takahiro;Koh, Katsuyoshi;Hanada, Ryoji
造血干细胞移植（HSCT）受者感染水痘带状疱疹病毒（VZV）的风险很高。尽管 VZV 疫苗接种可能有益于预防 VZV 感染，但有关 HSCT 受者中 VZV 疫苗（尤其是带状疱疹疫苗）安全性和有效性的数据有限。我们报告了在儿科同种异体 HSCT 受者中使用单剂 Oka 株高滴度带状疱疹等效水痘疫苗的经验。我们对 31 名没有疫苗型 VZV 感染的儿科同种异体 HSCT 受者接种了高滴度 VZV 疫苗。一名患者在接种疫苗 13 天后因野生型水痘带状疱疹病毒而患上水痘。在接种疫苗后 4.8 年的中位随访期内，未出现带状疱疹。没有观察到其他不良反应。 31 名患者中有 18 名（581%）在接种疫苗后呈血清阳性。 17名患者在HSCT后24个月内接种了疫苗；这些患者的血清阳性率与 HSCT 后 24 个月以上接种疫苗的患者的血清阳性率没有显着差异。接种水痘带状疱疹病毒疫苗可能是预防造血干细胞移植后水痘带状疱疹病毒感染的安全且有益的方法。 (C) 2016 年美国血液和骨髓移植协会。
Hematopoietic stem cell transplantation (HSCT) recipients have a high risk of varicella-zoster virus (VZV) infections. Although VZV vaccination may be beneficial in preventing VZV infections, data on safety and efficacy of VZV vaccines in HSCT recipients, particularly of zoster vaccine, are limited. We report our experience with the use of a single dose of an Oka strain high-titer zoster-equivalent varicella vaccine in pediatric allogeneic HSCT recipients. We administered the high-titer VZV vaccine to 31 pediatric allogeneic HSCT recipients without vaccine-type VZV infections. One patient developed varicella due to wild-type VZV 13 days after vaccination. No zoster developed after vaccination during a median follow-up period of 4.8 years from vaccination. No other adverse effects were observed. Eighteen of the 31 patients (581%) were seropositive after vaccination. Seventeen patients were vaccinated within 24 months after HSCT; the seropositivity of these patients did not significantly differ from that of patients vaccinated >24 months after HSCT. VZV vaccination may be a safe and beneficial approach in preventing VZV infections after HSCT. (C) 2016 American Society for Blood and Marrow Transplantation.